Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03308721 · ClinicalTrials.gov registry record · Phase 1
Research Study Investigating Study Medicine (NNC9204-1177) for Weight Management in People With Overweight or Obesity
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 99
- Enrollment target
NCT03308721 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 99 participants.
The verdict
NCT03308721, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 99 participants
- Enrollment target
Study Summary
This study looks at a new study medicine for weight management in people with overweight or obesity. The aim of this study is to find out how safe and tolerable the study medicine is. The study also looks at how the study medicine behaves in the body and how it is removed from the body. Participants will either get NNC9204-1177 (the new study medicine) or placebo (a formula that looks like the study medicine but does not have active ingredients). Which treatment participants get will be decided by chance. NNC9204-1177 has not been approved by the United States Food and Drug Administration. Its use in this study is experimental. Participants will get 1 or more injections into the skin of the stomach area once each week for 12 weeks. The study will last for about 5 months. Participants will have 19 clinic visits with the study doctor. At certain times during the study, participants will have blood draws and 3 different kinds of electrocardiograms. Participants will answer mental health questionnaires. Women: Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.
Interventions
- DRUG PLACEBO
- DRUG NNC9204-1177 A 1.0 mg/mL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2017-10-16 |
| Est. Completion | 2020-01-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03308721
The ClinicalTrials.gov registry entry for NCT03308721 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PLACEBO is the first listed.
NCT03308721 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03308721 about?
NCT03308721 is a clinical study titled "Research Study Investigating Study Medicine (NNC9204-1177) for Weight Management in People With Overweight or Obesity". This study looks at a new study medicine for weight management in people with overweight or obesity. The aim of this study is to find out how safe and tolerable the study medicine is. The study also looks at how the study medicine behaves in the body and how it is removed from the body. Participant...
What is the current status of trial NCT03308721?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 99 participants. The study started on 2017-10-16. Estimated completion is 2020-01-03.
What interventions are being tested in trial NCT03308721?
The interventions under investigation include: PLACEBO (DRUG), NNC9204-1177 A 1.0 mg/mL (DRUG).
Who is sponsoring clinical trial NCT03308721?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.